Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.51 |
| ▸ | SFRP1 | Q8N474 | 3/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | STS | P08842 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1012382 | 1.00 | PDE4B (0.51) | PDE4BSFRP1ALOX12TGFBR1GPR119 | |
| SCHEMBL1012808 | 1.00 | PDE4B (0.51) | PDE4BSFRP1ALOX12TGFBR1GPR119 | |
| SCHEMBL1015807 | 0.90 | GPR119 (0.45) | PDE4BSFRP1ALOX12TGFBR1GPR119 | |
| SCHEMBL1015948 | 0.89 | STS (0.55) | PDE4BSFRP1ALOX12TGFBR1GPR119 | |
| SCHEMBL1015101 | 0.89 | SFRP1 (0.46) | PDE4BSFRP1GPR119HTR6STS | |
| SCHEMBL1015103 | 0.89 | SFRP1 (0.46) | PDE4BSFRP1GPR119HTR6STS | |
| SCHEMBL1015330 | 0.89 | GPR119 (0.43) | PDE4BSFRP1GPR119HTR6 | |
| SCHEMBL1016748 | 0.87 | SFRP1 (0.47) | PDE4BSFRP1GPR119HTR6STS | |
| SCHEMBL1014342 | 0.86 | HTR6 (0.46) | PDE4BSFRP1GPR119HTR6STS | |
| SCHEMBL1016558 | 0.86 | GPR119 (0.45) | PDE4BSFRP1GPR119HTR6STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2081890-B1 | ARYLSULFONYL PYRROLIDINES AS 5-HT6 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-01-12 | — | — | EP | disclosed |
| US-7776910-B2 | Arylsulfonyl pyrrolidines as 5-HT6 inhibitors | ROCHE PALO ALTO LLC (US) | 2010-08-17 | — | — | US | disclosed |
| US-20080167361-A1 | Arylsulfonyl pyrrolidines as 5-HT6 inhibitors | ROCHE PALO ALTO LLC | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167361-A1 | Arylsulfonyl pyrrolidines as 5-HT6 inhibitors | HTR6, HTR1B, HTR1F | PDE4B 1026/4885SFRP1 3537/4885ALOX12 3220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.